APELLIS PHARMACEUTICALS INC (APLS) Stock Fundamental Analysis
USA - NASDAQ:APLS - US03753U1060 - Common Stock
19.54 USD
+0.09 (+0.46%)
19.49 USD
-0.05 (-0.26%)
Overall APLS gets a fundamental rating of 5 out of 10. We evaluated APLS against 533 industry peers in the Biotechnology industry. APLS has only an average score on both its financial health and profitability. APLS is growing strongly while it is still valued neutral. This is a good combination! These ratings would make APLS suitable for growth investing!
1. Profitability
1.1 Basic Checks
In the past year APLS was profitable.
In the past year APLS had a positive cash flow from operations.
In the past 5 years APLS always reported negative net income.
In the past 5 years APLS always reported negative operating cash flow.
1.2 Ratios
APLS has a better Return On Assets (4.25%) than 91.18% of its industry peers.
Looking at the Return On Equity, with a value of 11.21%, APLS belongs to the top of the industry, outperforming 93.43% of the companies in the same industry.
APLS has a Return On Invested Capital of 8.15%. This is amongst the best in the industry. APLS outperforms 94.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.25% | ||
| ROE | 11.21% | ||
| ROIC | 8.15% |
ROA(3y)-58.39%
ROA(5y)-59.14%
ROE(3y)-247.4%
ROE(5y)-257.29%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
APLS's Profit Margin of 4.43% is amongst the best of the industry. APLS outperforms 90.62% of its industry peers.
APLS's Operating Margin of 7.91% is amongst the best of the industry. APLS outperforms 90.62% of its industry peers.
APLS has a Gross Margin of 88.85%. This is amongst the best in the industry. APLS outperforms 90.24% of its industry peers.
In the last couple of years the Gross Margin of APLS has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 7.91% | ||
| PM (TTM) | 4.43% | ||
| GM | 88.85% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.7%
GM growth 5YN/A
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), APLS is destroying value.
The number of shares outstanding for APLS has been increased compared to 1 year ago.
The number of shares outstanding for APLS has been increased compared to 5 years ago.
The debt/assets ratio for APLS has been reduced compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of 0.36, we must say that APLS is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 0.36, APLS is in the better half of the industry, outperforming 63.41% of the companies in the same industry.
APLS has a debt to FCF ratio of 5.78. This is a neutral value as APLS would need 5.78 years to pay back of all of its debts.
With an excellent Debt to FCF ratio value of 5.78, APLS belongs to the best of the industry, outperforming 91.37% of the companies in the same industry.
A Debt/Equity ratio of 0.90 indicates that APLS is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.90, APLS is doing worse than 75.42% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.9 | ||
| Debt/FCF | 5.78 | ||
| Altman-Z | 0.36 |
ROIC/WACC0.94
WACC8.65%
2.3 Liquidity
A Current Ratio of 3.54 indicates that APLS has no problem at all paying its short term obligations.
APLS's Current ratio of 3.54 is in line compared to the rest of the industry. APLS outperforms 42.21% of its industry peers.
A Quick Ratio of 3.10 indicates that APLS has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 3.10, APLS is doing worse than 60.04% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.54 | ||
| Quick Ratio | 3.1 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 116.40% over the past year.
APLS shows a strong growth in Revenue. In the last year, the Revenue has grown by 42.11%.
The Revenue has been growing by 127.23% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)116.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%463.04%
Revenue 1Y (TTM)42.11%
Revenue growth 3Y127.23%
Revenue growth 5YN/A
Sales Q2Q%132.98%
3.2 Future
Based on estimates for the next years, APLS will show a very strong growth in Earnings Per Share. The EPS will grow by 29.48% on average per year.
The Revenue is expected to grow by 14.42% on average over the next years. This is quite good.
EPS Next Y98.32%
EPS Next 2Y10.47%
EPS Next 3Y28.49%
EPS Next 5Y29.48%
Revenue Next Year25.24%
Revenue Next 2Y7.13%
Revenue Next 3Y11.62%
Revenue Next 5Y14.42%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 63.03 indicates a quite expensive valuation of APLS.
Compared to the rest of the industry, the Price/Earnings ratio of APLS indicates a rather cheap valuation: APLS is cheaper than 90.24% of the companies listed in the same industry.
The average S&P500 Price/Earnings ratio is at 25.07. APLS is valued rather expensively when compared to this.
APLS is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 63.03 | ||
| Fwd PE | N/A |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, APLS is valued cheaper than 92.50% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of APLS indicates a rather cheap valuation: APLS is cheaper than 93.62% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 31.38 | ||
| EV/EBITDA | 29.77 |
4.3 Compensation for Growth
APLS's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as APLS's earnings are expected to grow with 28.49% in the coming years.
PEG (NY)0.64
PEG (5Y)N/A
EPS Next 2Y10.47%
EPS Next 3Y28.49%
5. Dividend
5.1 Amount
APLS does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
19.54
+0.09 (+0.46%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners103.58%
Inst Owner Change-5.83%
Ins Owners3.77%
Ins Owner Change-0.04%
Market Cap2.47B
Revenue(TTM)1.02B
Net Income(TTM)44.99M
Analysts78.52
Price Target38.7 (98.06%)
Short Float %14.19%
Short Ratio5.69
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)34.57%
Min EPS beat(2)31.03%
Max EPS beat(2)38.1%
EPS beat(4)3
Avg EPS beat(4)-1.49%
Min EPS beat(4)-101.36%
Max EPS beat(4)38.1%
EPS beat(8)5
Avg EPS beat(8)-4.2%
EPS beat(12)7
Avg EPS beat(12)-3.46%
EPS beat(16)7
Avg EPS beat(16)-4.53%
Revenue beat(2)1
Avg Revenue beat(2)1.69%
Min Revenue beat(2)-7.17%
Max Revenue beat(2)10.55%
Revenue beat(4)2
Avg Revenue beat(4)-1.99%
Min Revenue beat(4)-16.4%
Max Revenue beat(4)10.55%
Revenue beat(8)4
Avg Revenue beat(8)-0.73%
Revenue beat(12)7
Avg Revenue beat(12)7.96%
Revenue beat(16)10
Avg Revenue beat(16)42.21%
PT rev (1m)1.64%
PT rev (3m)2.99%
EPS NQ rev (1m)-15.36%
EPS NQ rev (3m)-11.73%
EPS NY rev (1m)95.39%
EPS NY rev (3m)98.61%
Revenue NQ rev (1m)-3.32%
Revenue NQ rev (3m)-4.4%
Revenue NY rev (1m)2.99%
Revenue NY rev (3m)13.12%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 63.03 | ||
| Fwd PE | N/A | ||
| P/S | 2.43 | ||
| P/FCF | 31.38 | ||
| P/OCF | 31.29 | ||
| P/B | 6.15 | ||
| P/tB | 6.15 | ||
| EV/EBITDA | 29.77 |
EPS(TTM)0.31
EY1.59%
EPS(NY)-1.13
Fwd EYN/A
FCF(TTM)0.62
FCFY3.19%
OCF(TTM)0.62
OCFY3.2%
SpS8.05
BVpS3.18
TBVpS3.18
PEG (NY)0.64
PEG (5Y)N/A
Graham Number4.71
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.25% | ||
| ROE | 11.21% | ||
| ROCE | 10.32% | ||
| ROIC | 8.15% | ||
| ROICexc | 21.17% | ||
| ROICexgc | 21.17% | ||
| OM | 7.91% | ||
| PM (TTM) | 4.43% | ||
| GM | 88.85% | ||
| FCFM | 7.74% |
ROA(3y)-58.39%
ROA(5y)-59.14%
ROE(3y)-247.4%
ROE(5y)-257.29%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.7%
GM growth 5YN/A
F-Score7
Asset Turnover0.96
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.9 | ||
| Debt/FCF | 5.78 | ||
| Debt/EBITDA | 4.4 | ||
| Cap/Depr | 13.41% | ||
| Cap/Sales | 0.02% | ||
| Interest Coverage | 1.92 | ||
| Cash Conversion | 96.08% | ||
| Profit Quality | 174.81% | ||
| Current Ratio | 3.54 | ||
| Quick Ratio | 3.1 | ||
| Altman-Z | 0.36 |
F-Score7
WACC8.65%
ROIC/WACC0.94
Cap/Depr(3y)54.61%
Cap/Depr(5y)218.08%
Cap/Sales(3y)0.75%
Cap/Sales(5y)1.22%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)116.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%463.04%
EPS Next Y98.32%
EPS Next 2Y10.47%
EPS Next 3Y28.49%
EPS Next 5Y29.48%
Revenue 1Y (TTM)42.11%
Revenue growth 3Y127.23%
Revenue growth 5YN/A
Sales Q2Q%132.98%
Revenue Next Year25.24%
Revenue Next 2Y7.13%
Revenue Next 3Y11.62%
Revenue Next 5Y14.42%
EBIT growth 1Y136%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year161.68%
EBIT Next 3Y48.37%
EBIT Next 5Y34.79%
FCF growth 1Y112.3%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y112.37%
OCF growth 3YN/A
OCF growth 5YN/A
APELLIS PHARMACEUTICALS INC / APLS FAQ
Can you provide the ChartMill fundamental rating for APELLIS PHARMACEUTICALS INC?
ChartMill assigns a fundamental rating of 5 / 10 to APLS.
Can you provide the valuation status for APELLIS PHARMACEUTICALS INC?
ChartMill assigns a valuation rating of 5 / 10 to APELLIS PHARMACEUTICALS INC (APLS). This can be considered as Fairly Valued.
What is the profitability of APLS stock?
APELLIS PHARMACEUTICALS INC (APLS) has a profitability rating of 5 / 10.
What are the PE and PB ratios of APELLIS PHARMACEUTICALS INC (APLS) stock?
The Price/Earnings (PE) ratio for APELLIS PHARMACEUTICALS INC (APLS) is 63.03 and the Price/Book (PB) ratio is 6.15.